Entera Bio Details EB613 Phase 3 and Post-Hoc Phase 2 Findings

Entera Bio detailed a 900-patient, 12-month, placebo-controlled Phase 3 for EB613 and presented post-hoc Phase 2 findings suggesting greater anabolic effects and BMD gains in women with baseline T-scores ≤ −2.5.